IMPORTANCE: To our knowledge, the Oral Ponesimod Versus Teriflunomide In Relapsing Multiple Sclerosis (OPTIMUM) trial is the first phase 3 study comparing 2 oral disease-modifying therapies for relapsing multiple sclerosis (RMS). OBJECTIVE: To compare the efficacy of ponesimod, a selective sphingosine-1-phosphate receptor 1 (S1P1) modulator with teriflunomide, a pyrimidine synthesis inhibitor, approved for the treatment of patients with RMS. DESIGN, SETTING, AND PARTICIPANTS: This multicenter, double-blind, active-comparator, superiority randomized clinical trial enrolled patients from April 27, 2015, to May 16, 2019, who were aged 18 to 55 years and had been diagnosed with multiple sclerosis per 2010 McDonald criteria, with a relapsing course from the onset, Expanded Disability Status Scale (EDSS) scores of 0 to 5.5, and recent clinical or magnetic resonance imaging disease activity. INTERVENTIONS: Patients were randomized (1:1) to 20 mg of ponesimod or 14 mg of teriflunomide once daily and the placebo for 108 weeks, with a 14-day gradual up-titration of ponesimod starting at 2 mg to mitigate first-dose cardiac effects of S1P1 modulators and a follow-up period of 30 days. MAIN OUTCOMES AND MEASURES: The primary end point was the annualized relapse rate. The secondary end points were the changes in symptom domain of Fatigue Symptom and Impact Questionnaire-Relapsing Multiple Sclerosis (FSIQ-RMS) at week 108, the number of combined unique active lesions per year on magnetic resonance imaging, and time to 12-week and 24-week confirmed disability accumulation. Safety and tolerability were assessed. Exploratory end points included the percentage change in brain volume and no evidence of disease activity (NEDA-3 and NEDA-4) status. RESULTS: For 1133 patients (567 receiving ponesimod and 566 receiving teriflunomide; median [range], 37.0 [18-55] years; 735 women [64.9%]), the relative rate reduction for ponesimod vs teriflunomide in the annualized relapse rate was 30.5% (0.202 vs 0.290; P < .001); the mean difference in FSIQ-RMS, -3.57 (-0.01 vs 3.56; P < .001); the relative risk reduction in combined unique active lesions per year, 56% (1.405 vs 3.164; P < .001); and the reduction in time to 12-week and 24-week confirmed disability accumulation risk estimates, 17% (10.1% vs 12.4%; P = .29) and 16% (8.1% vs 9.9; P = .37), respectively. Brain volume loss at week 108 was lower by 0.34% (-0.91% vs -1.25%; P < .001); the odds ratio for NEDA-3 achievement was 1.70 (25.0% vs 16.4%; P < .001). Incidence of treatment-emergent adverse events (502 of 565 [88.8%] vs 499 of 566 [88.2%]) and serious treatment-emergent adverse events (49 [8.7%] vs 46 [8.1%]) was similar for both groups. Treatment discontinuations because of adverse events was more common in the ponesimod group (49 of 565 [8.7%] vs 34 of 566 [6.0%]). CONCLUSIONS AND RELEVANCE: In this study, ponesimod was superior to teriflunomide on annualized relapse rate reduction, fatigue, magnetic resonance imaging activity, brain volume loss, and no evidence of disease activity status, but not confirmed disability accumulation. The safety profile was in line with the previous safety observations with ponesimod and the known profile of other S1P receptor modulators. TRIAL REGISTRATION: ClinicalTrials.gov Identifier: NCT02425644.

Actelion Pharmaceuticals Part of Janssen Pharmaceutical Companies Allschwil Switzerland

Cleveland Clinic Cleveland Ohio

Department of Medicine University of Ottawa The Ottawa Hospital Research Institute Ottawa Ontario Canada

Department of Neurology 1st Medical Faculty Charles University Prague Czech Republic

Department of Neurology Neuroimmunology Multiple Sclerosis Center of Catalonia Vall d'Hebron University Hospital Barcelona Spain

DKD Helios Klinik Wiesbaden Wiesbaden Germany

Icahn School of Medicine at Mount Sinai New York New York

Institute of Clinical Neuroimmunology Ludwig Maximilians University Munich Munich Germany

Munich Cluster of Systems Neurology Ludwig Maximilians University Munich Munich Germany

Neurology and Research Center for Clinical Neuroimmunology and Neuroscience Basel Departments of Medicine Clinical Research Biomedicine and Biomedical Engineering University Hospital and University of Basel Basel Switzerland

Now with Clinical Research Department Galapagos GmbH Basel Switzerland

Sant'Andrea Multiple Sclerosis Centre Sapienza University of Rome Rome Italy

Zobrazit více v PubMed

Thompson AJ, Baranzini SE, Geurts J, Hemmer B, Ciccarelli O. Multiple sclerosis. Lancet. 2018;391(10130):1622-1636. doi:10.1016/S0140-6736(18)30481-1 PubMed DOI

Dobson R, Giovannoni G. Multiple sclerosis—a review. Eur J Neurol. 2019;26(1):27-40. doi:10.1111/ene.13819 PubMed DOI

Confavreux C, Vukusic S, Moreau T, Adeleine P. Relapses and progression of disability in multiple sclerosis. N Engl J Med. 2000;343(20):1430-1438. doi:10.1056/NEJM200011163432001 PubMed DOI

O’Connor P, Wolinsky JS, Confavreux C, et al. ; TEMSO Trial Group . Randomized trial of oral teriflunomide for relapsing multiple sclerosis. N Engl J Med. 2011;365(14):1293-1303. doi:10.1056/NEJMoa1014656 PubMed DOI

Confavreux C, O’Connor P, Comi G, et al. ; TOWER Trial Group . Oral teriflunomide for patients with relapsing multiple sclerosis (TOWER): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet Neurol. 2014;13(3):247-256. doi:10.1016/S1474-4422(13)70308-9 PubMed DOI

Kappos L, Radue EW, O’Connor P, et al. ; FREEDOMS Study Group . A placebo-controlled trial of oral fingolimod in relapsing multiple sclerosis. N Engl J Med. 2010;362(5):387-401. doi:10.1056/NEJMoa0909494 PubMed DOI

Fox RJ, Miller DH, Phillips JT, et al. ; CONFIRM Study Investigators . Placebo-controlled phase 3 study of oral BG-12 or glatiramer in multiple sclerosis. N Engl J Med. 2012;367(12):1087-1097. doi:10.1056/NEJMoa1206328 PubMed DOI

Gold R, Kappos L, Arnold DL, et al. ; DEFINE Study Investigators . Placebo-controlled phase 3 study of oral BG-12 for relapsing multiple sclerosis. N Engl J Med. 2012;367(12):1098-1107. doi:10.1056/NEJMoa1114287 PubMed DOI

Kappos L, Bar-Or A, Cree BAC, et al. ; EXPAND Clinical Investigators . Siponimod versus placebo in secondary progressive multiple sclerosis (EXPAND): a double-blind, randomised, phase 3 study. Lancet. 2018;391(10127):1263-1273. doi:10.1016/S0140-6736(18)30475-6 PubMed DOI

Hutchinson M, Kappos L, Calabresi PA, et al. ; AFFIRM and SENTINEL Investigators . The efficacy of natalizumab in patients with relapsing multiple sclerosis: subgroup analyses of AFFIRM and SENTINEL. J Neurol. 2009;256(3):405-415. doi:10.1007/s00415-009-0093-1 PubMed DOI

Ontaneda D, Tallantyre E, Kalincik T, Planchon SM, Evangelou N. Early highly effective versus escalation treatment approaches in relapsing multiple sclerosis. Lancet Neurol. 2019;18(10):973-980. doi:10.1016/S1474-4422(19)30151-6 PubMed DOI

Brown JWL, Coles A, Horakova D, et al. ; MSBase Study Group . Association of initial disease-modifying therapy with later conversion to secondary progressive multiple sclerosis. JAMA. 2019;321(2):175-187. doi:10.1001/jama.2018.20588 PubMed DOI PMC

Derfuss T, Mehling M, Papadopoulou A, Bar-Or A, Cohen JA, Kappos L. Advances in oral immunomodulating therapies in relapsing multiple sclerosis. Lancet Neurol. 2020;19(4):336-347. doi:10.1016/S1474-4422(19)30391-6 PubMed DOI

D’Ambrosio D, Freedman MS, Prinz J. Ponesimod, a selective S1P1 receptor modulator: a potential treatment for multiple sclerosis and other immune-mediated diseases. Ther Adv Chronic Dis. 2016;7(1):18-33. doi:10.1177/2040622315617354 PubMed DOI PMC

Piali L, Froidevaux S, Hess P, et al. . The selective sphingosine 1-phosphate receptor 1 agonist ponesimod protects against lymphocyte-mediated tissue inflammation. J Pharmacol Exp Ther. 2011;337(2):547-556. doi:10.1124/jpet.110.176487 PubMed DOI

Chun J, Hla T, Lynch KR, Spiegel S, Moolenaar WH. International Union of Basic and Clinical Pharmacology: LXXVIII, lysophospholipid receptor nomenclature. Pharmacol Rev. 2010;62(4):579-587. doi:10.1124/pr.110.003111 PubMed DOI PMC

Brossard P, Derendorf H, Xu J, Maatouk H, Halabi A, Dingemanse J. Pharmacokinetics and pharmacodynamics of ponesimod, a selective S1P1 receptor modulator, in the first-in-human study. Br J Clin Pharmacol. 2013;76(6):888-896. doi:10.1111/bcp.12129 PubMed DOI PMC

Krause A, Brossard P, D’Ambrosio D, Dingemanse J. Population pharmacokinetics and pharmacodynamics of ponesimod, a selective S1P1 receptor modulator. J Pharmacokinet Pharmacodyn. 2014;41(3):261-278. doi:10.1007/s10928-014-9362-4 PubMed DOI

Olsson T, Boster A, Fernández Ó, et al. . Oral ponesimod in relapsing-remitting multiple sclerosis: a randomised phase II trial. J Neurol Neurosurg Psychiatry. 2014;85(11):1198-1208. doi:10.1136/jnnp-2013-307282 PubMed DOI PMC

Polman CH, Reingold SC, Banwell B, et al. . Diagnostic criteria for multiple sclerosis: 2010 revisions to the McDonald criteria. Ann Neurol. 2011;69(2):292-302. doi:10.1002/ana.22366 PubMed DOI PMC

Hudgens S, Schüler R, Stokes J, Eremenco S, Hunsche E, Leist TP. Development and validation of the FSIQ-RMS: a new patient-reported questionnaire to assess symptoms and impacts of fatigue in relapsing multiple sclerosis. Value Health. 2019;22(4):453-466. doi:10.1016/j.jval.2018.11.007 PubMed DOI

Schwab SR, Cyster JG. Finding a way out: lymphocyte egress from lymphoid organs. Nat Immunol. 2007;8(12):1295-1301. doi:10.1038/ni1545 PubMed DOI

Smith SM, De Stefano N, Jenkinson M, Matthews PM. Normalized accurate measurement of longitudinal brain change. J Comput Assist Tomogr. 2001;25(3):466-475. doi:10.1097/00004728-200105000-00022 PubMed DOI

Sormani MP, Kappos L, Radue EW, et al. . Defining brain volume cutoffs to identify clinically relevant atrophy in RRMS. Mult Scler. 2017;23(5):656-664. doi:10.1177/1352458516659550 PubMed DOI

Kappos L, De Stefano N, Freedman MS, et al. . Inclusion of brain volume loss in a revised measure of ‘no evidence of disease activity’ (NEDA-4) in relapsing-remitting multiple sclerosis. Mult Scler. 2016;22(10):1297-1305. doi:10.1177/1352458515616701 PubMed DOI PMC

Bretz F, Maurer W, Brannath W, Posch M. A graphical approach to sequentially rejective multiple test procedures. Stat Med. 2009;28(4):586-604. doi:10.1002/sim.3495 PubMed DOI

Lublin F. Multiple sclerosis trial designs for the 21st century: building on recent lessons. J Neurol. 2005;252(5)(suppl 5):v46-v53. doi:10.1007/s00415-005-5008-1 PubMed DOI

Janardhan V, Bakshi R. Quality of life in patients with multiple sclerosis: the impact of fatigue and depression. J Neurol Sci. 2002;205(1):51-58. doi:10.1016/S0022-510X(02)00312-X PubMed DOI

Ayache SS, Chalah MA. Fatigue in multiple sclerosis—insights into evaluation and management. Neurophysiol Clin. 2017;47(2):139-171. doi:10.1016/j.neucli.2017.02.004 PubMed DOI

Chalah MA, Riachi N, Ahdab R, Créange A, Lefaucheur JP, Ayache SS. Fatigue in multiple sclerosis: neural correlates and the role of non-invasive brain stimulation. Front Cell Neurosci. 2015;9:460. doi:10.3389/fncel.2015.00460 PubMed DOI PMC

Sormani MP, Arnold DL, De Stefano N. Treatment effect on brain atrophy correlates with treatment effect on disability in multiple sclerosis. Ann Neurol. 2014;75(1):43-49. doi:10.1002/ana.24018 PubMed DOI

Pichler A, Khalil M, Langkammer C, et al. . Combined analysis of global and compartmental brain volume changes in early multiple sclerosis in clinical practice. Mult Scler. 2016;22(3):340-346. doi:10.1177/1352458515593405 PubMed DOI

Radue EW, Barkhof F, Kappos L, et al. . Correlation between brain volume loss and clinical and MRI outcomes in multiple sclerosis. Neurology. 2015;84(8):784-793. doi:10.1212/WNL.0000000000001281 PubMed DOI PMC

Radue EW, Sprenger T, Gaetano L, et al. . Teriflunomide slows BVL in relapsing MS: a reanalysis of the TEMSO MRI data set using SIENA. Neurol Neuroimmunol Neuroinflamm. 2017;4(5):e390. doi:10.1212/NXI.0000000000000390 PubMed DOI PMC

Cohen JA, Comi G, Selmaj KW, et al. ; RADIANCE Trial Investigators . Safety and efficacy of ozanimod versus interferon beta-1a in relapsing multiple sclerosis (RADIANCE): a multicentre, randomised, 24-month, phase 3 trial. Lancet Neurol. 2019;18(11):1021-1033. doi:10.1016/S1474-4422(19)30238-8 PubMed DOI

Calabresi PA, Radue EW, Goodin D, et al. . Safety and efficacy of fingolimod in patients with relapsing-remitting multiple sclerosis (FREEDOMS II): a double-blind, randomised, placebo-controlled, phase 3 trial. Lancet Neurol. 2014;13(6):545-556. doi:10.1016/S1474-4422(14)70049-3 PubMed DOI

Hauser SL, Bar-Or A, Comi G, et al. ; OPERA I and OPERA II Clinical Investigators . Ocrelizumab versus interferon Beta-1a in relapsing multiple sclerosis. N Engl J Med. 2017;376(3):221-234. doi:10.1056/NEJMoa1601277 PubMed DOI

Hatcher SE, Waubant E, Nourbakhsh B, Crabtree-Hartman E, Graves JS. Rebound syndrome in patients with multiple sclerosis after cessation of fingolimod treatment. JAMA Neurol. 2016;73(7):790-794. doi:10.1001/jamaneurol.2016.0826 PubMed DOI

Freedman MS, Pozzilli C, Havrdova EK, et al. . Long-term efficacy and safety of ponesimod, an oral S1P1 receptor modulator: results from randomized phase ii core and extension studies in relapsing-remitting multiple sclerosis (1752). Neurology. 2020;94(15 supplement):1752. PubMed PMC

Managing multiple sclerosis in individuals aged 55 and above: a comprehensive review

Bioavailable central nervous system disease-modifying therapies for multiple sclerosis

Long-term safety and efficacy of ozanimod in relapsing multiple sclerosis: Up to 5 years of follow-up in the DAYBREAK open-label extension trial

Long-term Treatment With Ponesimod in Relapsing-Remitting Multiple Sclerosis: Results From Randomized Phase 2b Core and Extension Studies

Zobrazit více v PubMed

ClinicalTrials.gov
NCT02425644